Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey

Hemophilia A is characterized by a deficiency of clotting factor VIII (FVIII) requiring lifelong prophylactic treatment, typically with recombinant FVIII. In recent years, drugs with extended half-lives have become available, including damoctocog alfa pegol (Bayer S.p.A.). The clinical efficacy and...

Full description

Bibliographic Details
Main Author:	Ezio Zanon
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Pharmaceuticals
Subjects:	Hemophilia A coagulation factor VIII deficiency prophylaxis damoctocog alfa pegol
Online Access:	https://www.mdpi.com/1424-8247/16/9/1195

Similar Items

Cost analysis comparison of rurioctocog alfa pegol compared to turoctocog alfa pegol in the prophylaxis of Haemophilia A in Italy
by: Federica Demma, et al.
Published: (2022-06-01)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
by: Steven R. Lentz, et al.
Published: (2022-02-01)

Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis
by: Chonlatis Srichumpuang, et al.
Published: (2024-03-01)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
by: Eichler H, et al.
Published: (2023-11-01)

Treatment With Efmoroctocog Alfa (Elocta®) in Hemophilia: A Case Series
by: Ezio Zanon, et al.
Published: (2020-10-01)

Switching to nonacog beta pegol in hemophilia B: Outcomes from a Canadian real‐world, multicenter, retrospective study
by: Davide Matino, et al.
Published: (2022-03-01)

Tailored therapy with turoctocog alfa pegol according to patient’s lifestyle and hemorrhagic phenotype: from clinical trial to real-life
by: Ilaria Nichele, et al.
Published: (2024-04-01)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
by: Saunya Dover, et al.
Published: (2020-02-01)

Clinical and Laboratory Approaches to Hemophilia A
by: Hassan Mansouritorghabeh
Published: (2015-05-01)

Nonacog beta pegol (N9‐GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients
by: Anthony K. Chan, et al.
Published: (2020-10-01)

Prophylaxis in Hemophilia
by: Júlia Plentz Portich, et al.
Published: (2023-05-01)

Personalised Prophylaxis in a Child with Haemophilia A and Type 1 Diabetes
by: Maria Sol Cruz, et al.
Published: (2021-05-01)

Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
by: Johnny Mahlangu, et al.
Published: (2021-08-01)

Chinese Expert Consensus on Pharmacokinetics Guided Treatment for Hemophilia A
by: Hemophilia Treatment Center Collaborative Network of China
Published: (2022-10-01)

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials
by: Kenet G, et al.
Published: (2023-06-01)

Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience
by: Karla Rener, et al.
Published: (2023-11-01)

Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
by: Michael U. Callaghan, et al.
Published: (2022-08-01)

Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study)
by: Tine M.H.J. Goedhart, et al.
Published: (2022-01-01)

Immunogenicity of Current and New Therapies for Hemophilia A
by: Alessandra N. L. Prezotti, et al.
Published: (2022-07-01)

A Rare Case of Acquired Hemophilia A in Adolescents and Young Adults
by: Min Jeong Lee, et al.
Published: (2022-04-01)

Cost-effectiveness analysis of low-dose prophylaxis versus on-demand treatment for moderate-to-severe hemophilia A in India
by: Tulika Seth, et al.
Published: (2023-12-01)

Evaluation of the efficacy and safety of human coagulation factor Ⅷ in the treatment of hemophilia A patients
by: Ruyi CHEN, et al.
Published: (2022-12-01)

Acquired Hemophilia A with Gastrointestinal Bleeding
by: Narae Park, et al.
Published: (2020-01-01)

Efficacy and safety evaluation of plasma-derived human coagulation factor Ⅷ in patients with hemophilia A
by: Shumin LIANG, et al.
Published: (2023-09-01)

Bispecific Antibodies and Advances in Non–Gene Therapy Options in Hemophilia
by: Midori Shima
Published: (2020-05-01)

Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States
by: Wu Y, et al.
Published: (2022-09-01)

Polyethylene glycol 20 kDa-induced vacuolation does not impair phagocytic function of human monocyte-derived macrophages
by: Anne Schoenbrunn, et al.
Published: (2022-07-01)

Global coagulation assays in hemophilia A: A comparison to conventional assays
by: Saman Aghighi, et al.
Published: (2020-02-01)

Effect of tertiary prophylaxis with low-dose factor VIII in quality of life in adult patients with severe hemophilia A
by: Prakas Kumar Mandal, et al.
Published: (2019-01-01)

Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5)
by: Renchi Yang, et al.
Published: (2022-02-01)

Flow Cytometry Evaluation of Blood-Cell-Bound Surface FVIII in Hemophilia A and Thrombosis
by: Anjud Al-Mohannadi, et al.
Published: (2025-01-01)

Disappearance of Acquired Hemophilia A after Complete Remission in a Multiple Myeloma Patient
by: Vanessa Innao, et al.
Published: (2017-05-01)

MYOCARDIAL INFARCTION AND HEMOPHILIA
by: A. S. Galyavich, et al.
Published: (2016-03-01)

Extended half‐life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products
by: Jerome Teitel, et al.
Published: (2021-02-01)

Spontaneous Retroperitoneal Hemorrhage Caused by Idiopathic Acquired Hemophilia A Misdiagnosed as a Delayed Traumatic Hematoma: A Case Report
by: Seon Hee Kim, et al.
Published: (2019-10-01)

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review
by: Jacky K. Yu, et al.
Published: (2019-07-01)

Hematuria in aging men with hemophilia: Association with factor prophylaxis
by: Christian Qvigstad, et al.
Published: (2020-02-01)

Impact of novel hemophilia therapies around the world
by: Margareth C. Ozelo, et al.
Published: (2022-03-01)

Clinical case of an acquired hemophilia
by: P. N. Barlamov, et al.
Published: (2020-01-01)

Monitoring standard and extended half‐life products in hemophilia: Assay discrepancies for factor VIII and IX in pre‐ and postinfusion samples
by: Cecilia Augustsson, et al.
Published: (2020-10-01)